Cargando…

Platelet BACE1 levels as a possible biomarker for Alzheimer’s disease

Detalles Bibliográficos
Autores principales:	Decourt, Boris, Walker, Aaron, Gonzales, Amanda, Malek-Ahmadi, Michael, Liesback, Carolyn, Davis, Kathryn, Belden, Christine, Jacobson, Sandra, Sabbagh, Marwan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846840/ http://dx.doi.org/10.1186/1750-1326-8-S1-P14

Ejemplares similares

Sensitivity to change and prediction of global change for the Alzheimer’s Questionnaire
por: Malek-Ahmadi, Michael, et al.
Publicado: (2015)

Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment
por: Malek-Ahmadi, Michael, et al.
Publicado: (2012)

The Cause of Alzheimer’s Disease: The Theory of Multipathology Convergence to Chronic Neuronal Stress
por: Decourt, Boris, et al.
Publicado: (2022)

Does Informant-Based Reporting of Cognitive Decline Correlate with Age-Adjusted Hippocampal Volume in Mild Cognitive Impairment and Alzheimer’s Disease?
por: Sabbagh, Marwan, et al.
Publicado: (2021)

The influence of Apolipoprotein E genotype on regional pathology in Alzheimer’s disease
por: Sabbagh, Marwan N, et al.
Publicado: (2013)

Recent Perspectives on APP, Secretases, Endosomal Pathways and How they Influence Alzheimer’s Related Pathological Changes in Down Syndrome
por: DeCourt, Boris, et al.
Publicado: (2013)

Is diabetes associated with increased pathological burden in Alzheimer's disease?
por: Sadrolashrafi, Kaviyon, et al.
Publicado: (2021)

Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimer’s Disease
por: Hunter, Jesse M., et al.
Publicado: (2012)

Review of Advanced Drug Trials Focusing on the Reduction of Brain Beta-Amyloid to Prevent and Treat Dementia
por: Decourt, Boris, et al.
Publicado: (2022)

KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimer's Disease Patients
por: Malek-Ahmadi, Michael, et al.
Publicado: (2013)

Differences in Cerebrospinal Fluid Biomarkers between Clinically Diagnosed Idiopathic Normal Pressure Hydrocephalus and Alzheimer’s Disease
por: Tsai, Andrew, et al.
Publicado: (2014)

Critical Appraisal of Amyloid Lowering Agents in AD
por: Decourt, Boris, et al.
Publicado: (2021)

Role of BACE1 in Alzheimer’s synaptic function
por: Das, Brati, et al.
Publicado: (2017)

MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease
por: Decourt, Boris, et al.
Publicado: (2020)

Cerebral blood flow in Alzheimer’s disease
por: Roher, Alex E, et al.
Publicado: (2012)

Quantitative Appraisal of Ventricular Cerebrospinal Fluid Biomarkers in Neuropathologically Diagnosed Parkinson’s Disease Cases Lacking Alzheimer’s Disease Pathology
por: Maarouf, Chera L., et al.
Publicado: (2013)

Functions of the Alzheimer’s Disease Protease BACE1 at the Synapse in the Central Nervous System
por: Munro, Kathryn M., et al.
Publicado: (2016)

The Alzheimer's disease β-secretase enzyme, BACE1
por: Cole, Sarah L, et al.
Publicado: (2007)

Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment
por: Coimbra, Judite R. M., et al.
Publicado: (2018)

Post-Translational Modifications of BACE1 in Alzheimer's Disease
por: Wen, Wen, et al.
Publicado: (2022)

The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
por: Neumann, Ulf, et al.
Publicado: (2018)

BACE1, the Alzheimer's beta-secretase enzyme, in health and disease
por: Vassar, Robert
Publicado: (2012)

BACE1, the Alzheimer’s beta-secretase enzyme, in health and disease
por: Vassar, Robert
Publicado: (2013)

BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
por: Vassar, Robert
Publicado: (2014)

BACE1 inhibition as a therapeutic strategy for Alzheimer's disease
por: Vassar, Robert
Publicado: (2016)

BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease
por: Maia, Miguel A., et al.
Publicado: (2019)

BACE1: from biomarker to Alzheimer’s disease therapeutical target
por: Cervellati, Carlo, et al.
Publicado: (2021)

BACE2: A Promising Neuroprotective Candidate for Alzheimer’s Disease
por: Yeap, Yee Jie, et al.
Publicado: (2023)

BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer’s Disease Markers in Elderly Healthy Participants
por: Timmers, Maarten, et al.
Publicado: (2017)

PS1 Affects the Pathology of Alzheimer’s Disease by Regulating BACE1 Distribution in the ER and BACE1 Maturation in the Golgi Apparatus
por: Li, Nuomin, et al.
Publicado: (2022)

Investigational drugs for the treatment of AD: what can we learn from negative trials?
por: Jacobson, Sandra A, et al.
Publicado: (2011)

BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
por: Sjölander, Annica, et al.
Publicado: (2010)

Is There Inflammatory Synergy in Type II Diabetes Mellitus and Alzheimer's Disease?
por: Lue, Lih-Fen, et al.
Publicado: (2012)

BACE1 Inhibitors for Alzheimer’s Disease: The Past, Present and Any Future?
por: Bazzari, Firas H., et al.
Publicado: (2022)

Alzheimer's disease drug development pipeline: 2019
por: Cummings, Jeffrey, et al.
Publicado: (2019)

Alzheimer's disease drug development pipeline: 2020
por: Cummings, Jeffrey, et al.
Publicado: (2020)

Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice
por: Shimshek, Derya R., et al.
Publicado: (2016)

Essential Tremor in the Elderly and Risk for Dementia
por: Shill, Holly A., et al.
Publicado: (2014)

Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment
por: Dugger, Brittany N., et al.
Publicado: (2015)

Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
por: Sabbagh, Marwan N., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_oljdbkhprd96hpl8mr2b74e3i6